IRLAB receives additional patent for its drug candidate Pirepemat, expanding patent protection in the US

GOTHENBURG, SE / ACCESSWIRE / September 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 18, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that a new patent has been granted in the U.S. for a salt of its drug candidate pirepemat. The patent covers the active pharmaceutical ingredient used in the ongoing clinical development of pirepemat.

“Today’s patent grant is an important addition to IRLAB’s already strong patent portfolio for pirepemat. The patent portfolio offers potential market exclusivity into the early 2040s in most major geographic areas. The granting of this new patent brings a substantial increase in the commercial value of the pirepemat program,” says Kristina Torfgård, CEO of IRLAB.